IDEA AG announces successful completion of its pivotal Ph III study in Europe and reacquisition of rights to the targeted analgesic IDEA-033

(PresseBox) (Munich, 08/02/2006)

IDEA AG announces successful completion of its pivotal Ph III study in Europe and reacquisition of rights to the targeted analgesic IDEA-033

A story by IDEA AG

Published on 08/02/2006

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.

IDEA AG

Frankfurter Ring 193a 80807 München, Germany
+49 89 3246330
http://www.idea-ag.de

Actions

Get QR Code

You will also receive a separate filtered feed for each category of PresseBox. Additionally, in each newsroom you will find a subscribe button with further individual RSS feeds. There is also a corresponding Facebook page for each category.

Select a category to view the associated URL.

IDEA AG announces successful completion of its pivotal Ph III study in Europe and reacquisition of rights to the targeted analgesic IDEA-033

Inactive